semaglutide
semaglutide: developed by 1 company · 114 clinical trials tracked · 1 FDA decision.
semaglutide evidence translation
What we can confirm
1 FDA record · 114 tracked trials
What it means
What to watch
Prepared research question
How could semaglutide → NVO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 8 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Novo Nordisk A/S (NVO) | Approved |
Clinical Trials (114)showing 10 most recent
A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and Obesity
Primary endpoint: BPI-SF Pain Severity Scale
GLOW (GLP-1 Plus Lifestyle for Overall Wellness)
Primary endpoint: Body Mass Index (BMI) Reduction
A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy
Primary endpoint: Vanguard phase: Feasibility - Recruitment
Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)
Primary endpoint: Relative change in body weight
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
Primary endpoint: Part A: Number of treatment emergent adverse events (TEAE)
Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity
Primary endpoint: Relative change in body weight
A Multicenter, Randomized, Open-Label, Semaglutide Injection-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With Metformin Alone or in Combination With Sulfonylurea/Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Therapy (UNIGUIDE-2)
Primary endpoint: HbA1c
CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)
Primary endpoint: Two-level reduction in the World Health Organization (WHO) risk drinking level assessed in the last 28 days of intervention
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)
Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c)
Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study
Primary endpoint: UBT251: Change in glycated haemoglobin (HbA1c)
FDA Decisions1 records
Frequently asked questions
Who is developing semaglutide?
semaglutide is being developed by Novo Nordisk A/S.
How many clinical trials involve semaglutide?
BioSniper tracks 114 clinical trials involving semaglutide.
What is semaglutide's latest FDA decision?
The most recent tracked FDA decision for semaglutide is Approval for 1 INDICATIONS AND USAGE RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet , dated January 16, 2020.